Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO). The company is looking to consolidate its older drug, Nuplazid, while boosting its ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead ...

ACADIA Pharmaceuticals (NASDAQ:ACAD) highlighted its growing commercial portfolio, upcoming clinical catalysts, and cash ...

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives outlined the company’s revenue outlook, commercial priorities for its two ...

Both Acadia Pharmaceuticals and e-therapeutics pulled back the curtain this week on new looks for their respective corporate brand identities. E-therapeutics was the more drastic makeover of the two.

Acadia Pharmaceuticals (ACAD) Inc. announced it has entered into an exclusive worldwide license agreement with Saniona for the development and commercialization of SAN711, a first-in-class, highly ...